| abstract |
FIELD: pharmaceutics. n SUBSTANCE: group of inventions relates to aqueous compositions for anti-IL17a antibodies. An aqueous pharmaceutical composition suitable for parenteral administration to a subject to inhibit the activity of an IL17a protein contains pharmaceutically effective amount of an anti-IL17a antibody containing a VHH-derivative domain and a variable V L domain; a histidine-based buffer agent; and effective amount of sugar-based alcohol as an osmotic agent. Another option of an aqueous pharmaceutical composition, the use of an aqueous pharmaceutical composition for the treatment of an IL17a-mediated disease, a method for the treatment of an IL17a-mediated disease, a method for obtaining an aqueous pharmaceutical composition are also disclosed. n EFFECT: group of inventions provides colloidal stability, thermal stability, reduction of antibody aggregation and homogeneity of antibodies in the composition. n 37 cl, 33 dwg, 44 tbl, 10 ex |